viewErgomed PLC

Ergomed celebrates fourth licensing deal for anti-cancer compound

Ergomed jointly developed Zoptrex with AEterna Zentaris

Endometrial cancer
Zoptrex is a treatment for endometrial cancer

Clinical services specialist Ergomed Plc (LON:ERGO) said its co-development partner AEterna Zentaris Inc (TSE:AEX, NASDAQ:AEZS) has signed an additional licensing deal for cancer drug Zoptrex.

AEterna Zentaris signed an exclusive licence agreement with Specialised Therapeutics Asia for Zoptrex, covering the territories of Australia and New Zealand. It is the fourth licensing agreement for AEterna’s lead anti-cancer compound.

AEterna will receive an up-front payment plus milestone payments and royalties, while Ergomed will receive a portion of all revenues generated from the commercialisation of the product.

Zoptrex is currently in a fully-enrolled Phase 3 clinical trial for patients with cancer of the womb or uterus.  If the results of the trial warrant doing so, AEterna will submit a new drug application for Zoptrex to the United States Food and Drug Administration in 2017.

"This licensing agreement for Australia and New Zealand adds another two territories to the overall coverage now for Zoptrex and demonstrates the value of our co-development business,” said Dr Miroslav Reljanovic. 

“In line with our strategy to expand our co-development business, we also recently announced a new partnership, which, together with this licensing agreement, further validates our hybrid business model," he added.

Quick facts: Ergomed PLC

Price: 1000 GBX

Market: AIM
Market Cap: £487.2 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Ergomed PLC named herein, including the promotion by the Company of Ergomed PLC in any Content on the Site, the Company receives from said...


Expansion of Modus study 'great news for Ergomed Plc'

Ergomed Plc (LON:ERGO) has been cheered by news of progress in a medical study by one of its co-development partners, Modus Therapeutics. The pharma services and drug development group drew its shareholders’ attention to an announcement by Modus relating to Sevuparin, a new drug to treat...

on 11/16/2016

2 min read